311 related articles for article (PubMed ID: 12570013)
1. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs.
Rousseau A; Marquet P
Fundam Clin Pharmacol; 2002 Aug; 16(4):253-62. PubMed ID: 12570013
[TBL] [Abstract][Full Text] [Related]
2. Adaptive control methods for the dose individualisation of anticancer agents.
Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring of cancer chemotherapy.
Alnaim L
J Oncol Pharm Pract; 2007 Dec; 13(4):207-21. PubMed ID: 18045780
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.
Gotta V; Widmer N; Montemurro M; Leyvraz S; Haouala A; Decosterd LA; Csajka C; Buclin T
Clin Pharmacokinet; 2012 Mar; 51(3):187-201. PubMed ID: 22339450
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
6. Practical treatment guide for dose individualisation in cancer chemotherapy.
Canal P; Chatelut E; Guichard S
Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
[TBL] [Abstract][Full Text] [Related]
7. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.
Rousseau A; Sabot C; Delepine N; Delepine G; Debord J; Lachâtre G; Marquet P
Clin Pharmacokinet; 2002; 41(13):1095-104. PubMed ID: 12403645
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects].
Marquet P
Acta Clin Belg; 1999; 53 Suppl 1():2-12. PubMed ID: 10216973
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetically guided administration of chemotherapeutic agents.
van den Bongard HJ; Mathôt RA; Beijnen JH; Schellens JH
Clin Pharmacokinet; 2000 Nov; 39(5):345-67. PubMed ID: 11108434
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.
Loh GW; Ting LS; Ensom MH
Clin Pharmacokinet; 2007; 46(6):471-94. PubMed ID: 17518507
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics and individual dose adjustment of carboplatin].
Chatelut E; Canal P; Bugat R
Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
[TBL] [Abstract][Full Text] [Related]
13. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring in cancer management.
Galpin AJ; Evans WE
Clin Chem; 1993 Nov; 39(11 Pt 2):2419-30. PubMed ID: 8222253
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.
Etienne MC; Leger F; Pivot X; Chatelut E; Bensadoun RJ; Guardiola E; Renée N; Magné N; Canal P; Milano G
Ann Oncol; 2003 Apr; 14(4):643-7. PubMed ID: 12649114
[TBL] [Abstract][Full Text] [Related]
16. Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.
White-Koning M; Osborne C; Paci A; Boddy AV; Chatelut E; Veal GJ
Eur J Cancer; 2018 Mar; 91():56-67. PubMed ID: 29335155
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study.
Moeung S; Chevreau C; Broutin S; Guitton J; Lelièvre B; Ciccolini J; Massart C; Fléchon A; Delva R; Gravis G; Lotz JP; Bay JO; Gross-Goupil M; Paci A; Marsili S; Malard L; Chatelut E; Thomas F
Clin Cancer Res; 2017 Dec; 23(23):7171-7179. PubMed ID: 28928162
[No Abstract] [Full Text] [Related]
18. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes.
Masson E; Zamboni WC
Clin Pharmacokinet; 1997 Apr; 32(4):324-43. PubMed ID: 9113440
[TBL] [Abstract][Full Text] [Related]
19. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.
Peng B; Boddy AV; Cole M; Pearson AD; Chatelut E; Rubie H; Newell DR
Eur J Cancer; 1995 Oct; 31A(11):1804-10. PubMed ID: 8541105
[TBL] [Abstract][Full Text] [Related]
20. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?
Tod MM; Padoin C; Petitjean O
Clin Pharmacokinet; 2001; 40(11):803-14. PubMed ID: 11735603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
